STEFANUTTI, Claudia
 Distribuzione geografica
Continente #
NA - Nord America 5.895
EU - Europa 1.542
AS - Asia 601
AF - Africa 85
SA - Sud America 43
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 8.171
Nazione #
US - Stati Uniti d'America 5.853
IT - Italia 477
UA - Ucraina 409
IN - India 408
SE - Svezia 219
FI - Finlandia 200
CN - Cina 167
TG - Togo 79
GB - Regno Unito 62
CA - Canada 42
AR - Argentina 39
IE - Irlanda 38
DE - Germania 35
BG - Bulgaria 28
BE - Belgio 18
RO - Romania 15
NL - Olanda 13
RU - Federazione Russa 9
FR - Francia 6
HK - Hong Kong 6
SG - Singapore 6
AT - Austria 4
EU - Europa 4
ZA - Sudafrica 4
JP - Giappone 3
BR - Brasile 2
CH - Svizzera 2
CL - Cile 2
MY - Malesia 2
TR - Turchia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
EG - Egitto 1
ES - Italia 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
IR - Iran 1
KR - Corea 1
LT - Lituania 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
Totale 8.171
Città #
Fairfield 849
Woodbridge 540
Chandler 450
Houston 406
Ashburn 377
Ann Arbor 347
Seattle 306
Wilmington 300
Cambridge 238
Princeton 222
Plano 191
San Paolo di Civitate 190
Jacksonville 156
Rome 152
Boston 142
Beijing 134
Lawrence 123
Millbury 81
Lomé 79
San Diego 74
Fremont 63
Andover 61
Des Moines 43
Norwalk 41
Federal 39
Dublin 38
Dearborn 34
Boardman 28
Sofia 28
Toronto 27
Falls Church 20
New York 20
Chennai 18
Brussels 16
Ottawa 14
Buffalo 10
Southend 9
Hefei 8
Nanjing 8
San Francisco 7
San Mateo 7
Hong Kong 6
Indiana 6
Laurel 6
London 6
Redwood City 6
Auburn Hills 5
Redmond 5
Ancona 4
Bologna 4
Bühl 4
Chicago 4
Helsinki 4
Milan 4
Amsterdam 3
Bellevue 3
Florence 3
Kunming 3
Phoenix 3
Portland 3
Quartu Sant'Elena 3
Scalenghe 3
Tappahannock 3
Vienna 3
West Malling 3
Yellow Springs 3
Bagnolo Mella 2
Berlin 2
Bern 2
Chongqing 2
Como 2
Edinburgh 2
Ercolano 2
Hebei 2
Hyderabad 2
Istanbul 2
Jinan 2
Kilburn 2
Las Vegas 2
Los Angeles 2
Monteforte d'Alpone 2
Monterotondo 2
Muizenberg 2
Naples 2
Napoli 2
Olevano Romano 2
Pisa 2
Portici 2
Rosate 2
Sabaudia 2
Silverton 2
Tashkent 2
Vicenza 2
Villamagna 2
Waanrode 2
Acerra 1
Aradeo 1
Auckland 1
Bangkok 1
Bari 1
Totale 6.059
Nome #
Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. 116
Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis 96
Toward an international consensus - integrating lipoprotein apheresis and new lipid-lowering drugs 92
First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias 83
Therapeutic apheresis in low weight patients: Technical feasibility, tolerance, compliance, and risks 79
LDL-apheresis in a homozygous familial hypercholesterolemic child aged 4.5 77
EXTRACORPOREAL ATHEROGENIC LIPOPROTEIN REMOVAL IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 76
THE NATURAL-HISTORY OF GALLSTONES - THE GREPCO EXPERIENCE 74
Effects of CER-001 on carotid atherosclerosis by 3TMRI in homozygous familial hypercholesterolemia (HoFH): the modifying orphan disease evaluation (MODE) study 74
Therapeutic apheresis in pregnancy: three differential indications with positive maternal and fetal outcome 74
THE GREPCO STUDIES - METHODOLOGY, PREVALENCE AND INCIDENCE DATA 72
Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score 72
Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort 71
Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis 71
Atorvastatin Inhibits gp91(phox) Circulating Levels in Patients With Hypercholesterolemia 70
Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. 68
Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study 68
Low-density lipoprotein apheresis in a patient aged 3.5 years. 67
The 2009 2nd Italian Consensus Conference on LDL-apheresis 67
Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk 67
Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. 67
A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature 67
Association of serum selenium with selected cardiovascular risk factors 67
A new missense mutation (Cys 297- - Phe) of the low density lipoprotein receptor in italian patients with familial hypercholesterolemia (FH Trieste) 66
Identification and diagnosis of patients with familial chylomicronemia syndrome (FCS): Expert Panel recommendations and proposal of an FCS Score 65
Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia 65
Association of Serum Selenium with Selected Cardiovascular Risk Factors. 65
A three month-old infant with severe hyperchylomicronemia: Molecular diagnosis and extracorporeal treatment 64
LDL-apheresis in pediatric patients with severe hyperlipoproteinemia 64
Prevalence of gallstone disease in an Italian adult female population. 63
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study 62
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial 62
A multi-centre study on completeness of urine collection in 11 European centres. Some problems with the use of creatinine and 4-aminobenzoic acid as marker of the com¬pleteness of collection 61
Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion 61
Therapeutic plasma exchange in patients with severe hypertriglyceridemia: A multicenter study 60
Hijacked journals are emerging as a challenge for scholarly publishing 60
Hypertriglyceridaemia, Postprandial Lipaemia And Non-Hdl Cholesterol. 60
Platelet activation in hypercholesterolemic patients submitted to therapeutic plasmapheresis. An ultrastructural study 60
Gemfibrozil alone and combined with cholestyramine in the treatment of primary hyperlipoproteinemia. 59
Immunoadsorption apheresis (Selesorb ©) in the treatment of chronic hepatitis C virus (HCV)- related type 2 mixed cryglobulinemia. 59
Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia 59
Italian Multicenter Study on Low-Density Lipoprotein Apheresis Working Group 2009 Survey 59
Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. 59
ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia? 59
A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report 59
Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis 59
Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias 58
Clinical Trials in Apheresis 57
New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia 57
Aorta and Coronary Angiographic Follow-up of Children with Severe Hypercholesterolemia Treated with LDL Apheresis 56
Four novel partial deletions of LDL-receptor gene in Italian patients with familial hypercholesterolemia. 55
A new treatment of refractory ascites: Ascitoapheresis 55
Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis 55
Immunoadsorption Apheresis and Immunosuppressive Drug Therapy in the Treatment of Complicated HCV-Related Cryoglobulinemia 55
LDL-apheresis in the treatment of familial hypercholesterolemia in childhood 54
SERUM-LIPIDS AND GALLSTONE DISEASE 54
Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia 54
Scientific Information Security in Information Science and Academic Publishing 54
Simvastatin and pravastatin: a daily dose of 40 mg in the long-term treatment of primary hypercholesterolemia. 54
Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis 54
LIPOPROTEIN AND HEMOCOAGULATORY PARAMETERS DURING THERAPEUTIC PLASMAPHERESIS IN HOMOZYGOUS AND HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 54
Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia 54
DALI low-density lipoprotein apheresis in homozygous and heterozygous familial hypercholesterolemic patients using low-dose citrate anticoagulation. 52
Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9 52
Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonresponsive to drug therapy alone 52
Hypercholesterolemia alters the response of the plasma lipid profile and inflammatory markers to supplementation of the diet with n-3 polyunsaturated fatty acids from fish oil. 51
Obesity as a risk factor for gallstone disease: results of a six-years follow-up study. 50
The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update 50
Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial 50
EFFICACY OF ALIROCUMAB IN 1,191 PATIENTS WITH A WIDE SPECTRUM OF MUTATIONS IN GENES CAUSATIVE FOR FAMILIAL HYPERCHOLESTEROLEMIA 50
Different Hormonal Treatment In Pre- and Post-Menopausal Women: Effect on the Cardiovascular Risk 49
A MULTICENTER STUDY ON COMPLETENESS OF URINE COLLECTION IN 11 EUROPEAN CENTERS .1. SOME PROBLEMS WITH THE USE OF CREATININE AND 4-AMINOBENZOIC ACID AS MARKERS OF THE COMPLETENESS OF COLLECTION 49
Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care 49
Treatment of primary hypertriglyceridemia states - General approach and the role of extracorporeal methods 49
Lipoprotein Apheresis: state of the art and novelties 48
Corticosteroidi prenatali: cosa c'è di nuovo? 48
Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL apheresis 47
Targeting MTP for the treatment of homozygous familial hypercholesterolemia 47
Lipid apheresis in secondary cardiovascular risk prevention in HyperLp(a)lipidemia. Why not?. 47
DEXTRAN SULFATE CELLULOSE LDL-AFFINITY APHERESIS IN THE TREATMENT OF SEVERE FAMILIAL HYPERCHOLESTEROLEMIA AND NONFAMILIAL HYPERLIPOPROTEINEMIA - A CLINICAL REPORT ON 12 CASES 46
The Italian Registry of Pediatric Therapeutic Apheresis: a concise report on the 2005 activity 46
Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. 45
THE ITALIAN MULTICENTER STUDY ON LDL-APHERESIS: RETROSPECTIVE ANALYSIS (2007) 45
Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia 45
Severe Hypertriglyceridemia-Related Acute Pancreatitis 45
Pediatric LDL-apheresis: clinical experience in Italy’s largest sample. 44
Comparison between different techniques of LDL-apheresis 44
Prevalence of cholelithiasis in a female population and study of risk factors sex-related. 43
LDL-apheresis induced anti-oxidative modification of LDL 43
Treatment of Severe Genetic Dyslipidemia: Where Are We Going? 43
Therapeutic Plasmapheresis. A gate to an effective treatment of severe pathological conditions 43
Severe hypertriglyceridemia-related acute pancreatitis: Myth or reality? 43
SMOKING-HABITS AND RISK OF ASYMPTOMATIC CAROTID LESIONS IN A FREE-LIVING POPULATION-SAMPLE 42
H.E.L.P. LDL-apheresis clinical experience in Italy 42
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia 42
Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives 41
EFFECTS OF LOW DOSE ROSUVASTATIN AND ATORVASTATIN OVER 48 WEEKS TREATMENT IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA. 40
Plasma Lp(a) profile in patients with familial hypercholesterolemia treated by dextransulfate cellulose LDL-apheresis and plasma-exchange 40
Selective continuous removal of low density lipoproteins by dextran-sulfate cellulose column adsorption apheresis in the therapy of familial hypercholesterolemia. 40
Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia 40
Totale 5.767
Categoria #
all - tutte 21.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.269


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019626 0 0 0 0 0 0 0 0 0 127 290 209
2019/20201.738 293 66 24 88 137 213 211 211 171 152 120 52
2020/2021796 82 86 23 60 10 100 3 107 110 129 71 15
2021/20221.977 5 128 165 78 269 58 37 214 146 165 312 400
2022/20231.736 388 481 80 116 171 163 28 88 155 11 48 7
2023/2024405 59 109 19 46 42 62 7 41 5 15 0 0
Totale 8.500